Loading..

COMPANY OVERVIEW
VISEN is an innovative biopharmaceutical company focused on endocrine diseases. We are dedicated to providing innovative therapies and compassionate, patient-centric care, because we believe that achieving better treatment processes and outcomes results in living better lives. Putting patients’ need first, VISEN is committed to providing first-in-class or best-in-class products and treatments for endocrine diseases. Our therapeutic areas cover endocrine diseases in adults and children, and rare endocrine diseases.

VISEN comprises seasoned professionals with multinational pharmaceutical experiences and leverages cutting-edge technologies and leading resources across the world. We are focused on the Chinese market, and have established offices in Shanghai, Beijing, Hong Kong and Taipei. Our goal is to enable Chinese endocrine patients to benefit from the world's most advanced and reliable treatment solutions earlier.
VISEN Pharmaceuticals (VISEN), founded in 2018 jointly by Ascendis Pharma A/S, Vivo Capital and Sofinnova Investments, holds exclusive rights to develop, commercialize, and manufacture three innovative endocrinology drug candidates developed on TransCon technology platform by Ascendis Pharma A/S, in mainland China, Hong Kong, Macau, and Taiwan. VISEN strives to establish a recognized and leading franchise in endocrinology with “end-to-end” capabilities that integrate research and discovery, clinical development, commercialization, manufacturing and business development, and become a partner of choice for innovative endocrine treatment.
In Jan 2021, VISEN closed a $150 million Series B financing led by Hongshan (formerly known as Sequoia China) with participation from OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, as well as all three founding shareholders.